How Jeffrey A, Jazaeri Amir A
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Med. 2025 Jan 10;6(1):100558. doi: 10.1016/j.medj.2024.11.011.
Although there is anti-tumor efficacy of dual CTLA-4/PD-1 blockade in advanced/recurrent cervical cancer, it is unclear whether combination with chemotherapy is synergistic. In COMPASSION-16, Wu et al. demonstrated improved survival outcomes of cadolinimab plus chemotherapy compared to chemotherapy alone for first-line systemic therapy for advanced/recurrent cervical cancer, suggesting a potential role of bispecific CTLA-4/PD-1 inhibitors in the frontline setting..
尽管双重CTLA-4/PD-1阻断在晚期/复发性宫颈癌中具有抗肿瘤疗效，但尚不清楚与化疗联合是否具有协同作用。在COMPASSION-16研究中，Wu等人证明，对于晚期/复发性宫颈癌的一线全身治疗，卡多利单抗联合化疗的生存结果优于单纯化疗，这表明双特异性CTLA-4/PD-1抑制剂在一线治疗中具有潜在作用。
